Pharmacokinetics of a Novel Anagrelide Extended-Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product-Reference-Cited by-同舟云学术

Pharmacokinetics of a Novel Anagrelide Extended-Release Formulation in Healthy Subjects: Food Intake and Comparison With a Reference Product

Published:2017-03-16 Issue:2 Volume:7 Page:123-131
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Petrides Petro E.¹,Schoergenhofer Christian²,Widmann Rudolf³,Jilma Bernd²,Klade Christoph S.³

Affiliation:

1. Hematology Oncology Center and Ludwig Maximilians University of Munich Medical School; Munich Germany

2. Department of Clinical Pharmacology; Medical University of Vienna; Vienna Austria

3. AOP Orphan Pharmaceuticals AG; Vienna Austria

Funder

AOP Orphan Pharmaceuticals

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Reference28 articles.

1. Phase III, single-arm study investigating the efficacy, safety, and tolerability of anagrelide as a second-line treatment in high-risk Japanese patients with essential thrombocythemia;Kanakura;Int J Hematol,2014

2. Petrides PE Gisslinger H Baerlocher GM Grießhammer M Lengfelder E Essentielle (oder primäre) Thrombozythämie (ET) www.onkopedia.com/de/onkopedia/guidelines

3. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia;Spencer;Drugs.,1994

4. Anagrelide: a new drug for treating thrombocytosis;Silverstein;N Engl J Med.,1988

5. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers;Abe Andes;Thromb Haemost.,1984

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics, Safety, and Tolerance of Anagrelide, the First Domestic Generic, Compared with Reference Drug;Clinical oncohematology;2020

2. Emerging drugs for essential thrombocythemia;Expert Opinion on Emerging Drugs;2019-04-03

3. A phaseIIIrandomized, multicentre, double blind, active controlled trial to compare the efficacy and safety of two different anagrelide formulations in patients with essential thrombocythaemia – theTEAM‐ET2·0 trial;British Journal of Haematology;2019-03-28